The global gene therapy research and development market is forecast to expand significantly between 2025 and 2035, driven by advancements in treatments for cancer, rare diseases, cardiovascular disorders, ophthalmic conditions, hematological disorders, neurological diseases, and diabetes mellitus. The report highlights increasing investment in innovative therapeutics, regulatory support, and the adoption of precision medicine approaches as key factors accelerating market growth. The study also notes the growing importance of clinical pipeline expansion, new vector technologies, and scalable manufacturing processes as critical enablers for future gene therapy commercialization.
Leading companies shaping the market include BlueRock Therapeutics, American Gene Technologies, Applied Genetic, Astellas Pharma Inc., Bayer, Benitec BioPharma, Biogen, Bluebird Bio, Bristol Myers Squibb, Calimmune, Inc. (CSL Behiring), Cellectis, GenSight Biologics, Gilead Lifesciences, Inc., GQ Bio Therapeutics GmbH (Pacira Pharmaceuticals, Inc.), Novartis AG, OCUGEN, INC., Orchard Therapeutics, Oxford Biomedica, Pfizer, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Sanofi, Sarepta Therapeutics, Inc., Spark Therapeutics (Subsidiary of Roche), Takeda Pharmaceutical Company Limited, Taysha GTx, Transgene, UniQure N. V., VeonGen Therapeutics, Voyager Therapeutics Inc., 3SBio, Abeona, Arctic Therapeutics, Ayrmid, Belief BioMed, Carlyle, Chongqing Precision Biotech, Coave Therapeutics, Curocell, EnPlusOne Biosciences, EsoBiotec, Garuda Therapeutics, Helixmith, Hubble Therapeutics, Immunis, Imunopharm, Inceptor Bio, Inhibrx, Inc., iOncologi, MaxCyte, MorphoSys AG, Neumirna Therapeutics, Novo Holdings, Pacira BioSciences, Precigen, PulseSight Therapeutics, Reata Pharmaceuticals, Inc., RegCell, Regenxbio, Replimune, RheumaGen, RhyGaze, Rocket Pharmaceuticals, SeQure, SK Capital, Skyline Therapeutics, TargImmune Therapeutics, Tebao Biotechnology, Ultragenyx, and other related firms, all of which are actively developing therapies across diverse indications and advancing multiple gene therapy candidates through preclinical and clinical stages. According to the report, collaborations, licensing agreements, and strategic partnerships among these companies are further enhancing the pipeline and enabling broader access to gene therapy solutions globally.
The analysis emphasizes the potential for transformative treatments that address unmet medical needs, particularly in rare and difficult-to-treat conditions, and the market’s expansion is expected to be sustained by innovation in delivery methods, biomarker-driven patient selection, and regulatory approvals across key regions, including North America, Europe, and Asia-Pacific. The report indicates that gene therapy R&D will remain a high-growth segment within the biotechnology and pharmaceutical sectors throughout the forecast period.
